 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
Management
John D. Stanton
Co-chairman, Chief Executive Officer and Chief Financial Officer
Benedict S. Maniscalco
Co-chairman, Chief Medical Officer, Head of Operations
Scientific Directors
E. Olavi Kajander, M.D.,
Ph.D.
Chief Research and Science Officer
John D. Stanton
Co-chairman, Chief Executive Officer and Chief Financial Officer
From March, 2001 through the present, Mr. Stanton has served as our Chairman of the Board and Chief Financial Officer. From March 2001 through January 2004, Mr. Stanton served as Chief Executive Officer and since July 2004 took over that role again. From 1987 through the present, Mr. Stanton served as the President and Chief Executive Officer of Florida Engineered Construction Products, Corporation. Mr. Stanton has served as Chairman of the Board of Directors of publicly-traded EarthFirst Technologies, Inc. from May 15, 2000 through the present. Mr. Stanton also serves on the Med-Tech Board of Directors. Since the early 1990's, Mr. Stanton has been, and continues to be, involved in turn-around management for financially distressed companies, providing management guidance and financing. In 1981, Mr. Stanton assumed the role of Chief Financial Officer for Florida Engineered Construction Products, Corporation, a privately held manufacturer of residential and commercial construction products, located in Tampa, Florida. Mr. Stanton worked as an auditor with the international professional services firm that is now known as Ernst & Young, LLP from 1973 through 1981. A Vietnam veteran of the United States Army, he graduated from the University of South Florida with a Bachelors Degree in Marketing and Accounting in 1972, and with an MBA in 1973. Mr. Stanton earned the designation of Certified Public Accountant in 1974 and was a Sells Award winner in the CPA examination. Mr. Stanton is a lifetime resident of Tampa, Florida.
Benedict S. Maniscalco MD F.A.C.C.
Co-chairman, Chief Medical Officer, Head of Operations
Dr. Maniscalco received his Medical Degree from Duke
University School of Medicine and Residences and Fellowship in Cardiovascular
Diseases from Emory University affiliate Hospitals in 1975. He was an
Assistant Professor of Medicine (Cardiology) at the University of South
Florida College of Medicine. He co-founded St. Joseph’s Heart Institute
in Tampa, Florida and was Director of Cardiovascular Services from 1979
to 1997. He established a large multi specialty cardiovascular group
practice beginning in 1997. Over the years, he has been a member of
numerous local, state and national professional societies. He has served
as President and Governor of the Florida Chapter of the American College
of Cardiology and has been involved in numerous committees dealing with
socioeconomic and medical policies in the American College of Cardiology
and the Society for Cardiac Angiography and Interventions. He is a frequent
lecturer at local, state and national levels, on clinical and non-clinical
matters affecting delivery of cardiovascular services. He pioneered
some of the first observational studies on treatments for Calcifying
Nanoparticles.
E. Olavi Kajander, MD, Ph.D.
Chief Research and Science Officer
Dr. E. Olavi Kajander is Chief Research and Science Officer at Nanobac Pharmaceuticals in Tampa. He founded Nanobac OY, a Finnish research and development company located in Kuopio, Finland which is is now a subsidiary of Nanobac Pharmaceuticals. Dr. Kajander also founded Abcell Corporation, a medical diagnostics company.
Dr. Kajander is a professor at the University of Kuopio. His position at the University of Kuopio has elevated over the time of his tenure from Ph.D. candidate, to doctorate, assistant professor, associate professor and now as docent. He has taught many courses at the university for more than 12 years and was the Research Director in the Department of Biochemistry.
Dr. Kajander was a Scripps Clinic & Resident Foundation post-doctoral research fellow in La Jolla, California. He has authored or co-authored more than 70 scientific research papers and review articles, two letters and more than 50 scientific abstract publications as well as several invited editorials in scientific texts and journals. He also co-authored a Microbiology textbook chapter on Nanobacteria. He has been involved in the production of a number of videos and documentaries about his discovery of Nanobacteria. He pioneered families of U.S. patents effective in many countries and now assigned to Nanobac Pharmaceuticals.
Nanobac Pharmaceuticals, Inc.
3000 Bayport Drive, Suite 910
Tampa, Florida 33607
Ph. (813) 865-1125
Email us at:
